RxDoctor Payments Data

Dat Nguyen, DO

Interventional Cardiology · Plano, TXNPI 1295902047

Payments from drug & device makers

$3,477in general payments, 2019–2025

Across 86 payments — averaging $40.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Boston Scientific$880
  • Medtronic$299
  • Imperative Care, Inc$146
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$122
  • Merz North America, Inc.$116
  • plus $254 from 9 others

What the payments were for

  • Travel & lodging$63018%
  • Food & beverage$2,84682%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,477 in reported general payments places this provider in the 15th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$179,010
Medicare patients
394
Services billed
1,867

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban146$171,723
EntrestoSacubitril/Valsartan28$28,710
XareltoRivaroxaban26$20,703
Ranolazine ErRanolazine11$1,701
Metoprolol Succinate104$1,355
Nifedipine ErNifedipine42$764
ClopidogrelClopidogrel Bisulfate91$754
Atorvastatin Calcium131$688
Enoxaparin Sodium13$688
Losartan Potassium81$581
Amlodipine Besylate78$543
Rosuvastatin Calcium43$419
Pravastatin Sodium47$407
Isosorbide Mononitrate ErIsosorbide Mononitrate55$401
Lisinopril31$388

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$171,723146 claims
NovartisEntresto$43$28,71028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →